Compare NetEase Inc (NTES) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Novo Nordisk A/S — how do they compare? NetEase Inc trades at $124.27 (market cap $76.09B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.2× NetEase Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Novo Nordisk A/S for 116 Days on average.
| NTES | NVO | |
|---|---|---|
Market Cap | $76.09B | $165.31B |
Volume | 486,447 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $152.85 | $63.98 |
52-Week Low | $109.26 | $35.29 |
Typical Hold Time | 73 Days | 116 Days |
Enterprise Value | $51.81B | $179.56B |
Dividend Yield | 2.45% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $124.20, up 2.98% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 revenue growth of 8% year-over-year to $4.4 billion, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights focus on gaming performance and AI investments.
Outlook remains positive with an 81.82% analyst buy rating and a $168.00 consensus price target, implying significant upside. Risks include earnings volatility and competitive pressures in the gaming sector. The stock presents a value opportunity given its reasonable P/E of 15.92 and strong balance sheet with $137.58 billion in cash.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
